Yasir Y. Elamin

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.5K citations · Full text

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone, William N. William, Annikka Weissferdt et al. · Nature Medicine · 2021 · 582 citations · Full text

Neostar Trial, Medicine, Immune Checkpoint Inhibitor +6

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan et al. · Nature Medicine · 2018 · 443 citations · Full text

Tumor Biology, Oncology, Kinase Inhibitor +12

Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

Yanshuo Chu, Enyu Dai, Yating Li et al. · Nature Medicine · 2023 · 418 citations · Full text

Cancer Immunosurveillance, T-regulatory Cell, Immunology +10

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne Robichaux, Xiuning Le, R.S.K. Vijayan et al. · Nature · 2021 · 416 citations · Full text